Atreca, Inc. announced that Dr. Bartosz Chmielowski, Health Sciences Clinical Professor of Medicine in the Division of Hematology-Oncology at the University of California Los Angeles, presented safety and efficacy data from the ongoing Phase 1b study of ATRC-101 in patients with select advanced solid tumors cancer during an oral abstract session on Sunday, June 4 at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. The presentation provided a summary of clinical data collected as of a February 17, 2023, data cut-off date. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0898 USD | +0.90% | +12.25% | -31.97% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 10 | North American Morning Briefing : Traders Await -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.97% | 3.53M | |
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |
- Stock Market
- Equities
- BCEL Stock
- News Atreca, Inc.
- Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract